Tg Therapeutics (TGTX) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $390.9 million.
- Tg Therapeutics' Income towards Parent Company rose 1000623.06% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 321281.3%. This contributed to the annual value of $23.4 million for FY2024, which is 8452.49% up from last year.
- Tg Therapeutics' Income towards Parent Company amounted to $390.9 million in Q3 2025, which was up 1000623.06% from $28.2 million recorded in Q2 2025.
- Tg Therapeutics' 5-year Income towards Parent Company high stood at $390.9 million for Q3 2025, and its period low was -$94.0 million during Q4 2021.
- In the last 5 years, Tg Therapeutics' Income towards Parent Company had a median value of -$36.6 million in 2022 and averaged -$6.2 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 9660.49% in 2024, then soared by 1000623.06% in 2025.
- Over the past 5 years, Tg Therapeutics' Income towards Parent Company (Quarter) stood at -$94.0 million in 2021, then grew by 14.49% to -$80.4 million in 2022, then surged by 82.07% to -$14.4 million in 2023, then surged by 261.92% to $23.3 million in 2024, then surged by 1574.7% to $390.9 million in 2025.
- Its last three reported values are $390.9 million in Q3 2025, $28.2 million for Q2 2025, and $5.1 million during Q1 2025.